Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FeT is an investigational iron-based coordination complex composed of ferric ions (Fe3+), ferricyanide, and tartrate, structurally related to Prussian Blue. It is being researched as a potential antiproliferative agent, with studies demonstrating its ability to induce cell death in human bladder cancer cells (T24). The drug's mechanism of action involves the peroxidation of unsaturated fatty acids, leading to oxidative stress and the induction of ferroptosis. FeT self-assembles into drop-like nanostructures (10–130 nm) in aqueous solutions and can bind to albumin. Its activity is significantly enhanced by light, suggesting potential applications in photodynamic therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FeT.